IL3 Stock Chart & Stats
€14.40
€0.00(0.00%)
At close: 4:00 PM EDT
€14.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.60 - €17.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.10B
Enterprise Value€3.18K
Total Cash (Recent Filing)€274.08M
Total Debt (Recent Filing)€2.04B
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 04, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,772,510
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.96Price Target Upside10.84% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.12
Revenue Forecast (FY)€1.44B
Bulls Say, Bears Say
Bulls Say
Revenue And EPS ExecutionDelivering revenue growth alongside a 24% year-over-year increase in adjusted EPS indicates improving operating execution. Reaffirmed full-year guidance also supports confidence that Integra’s core procedure-driven portfolio can sustain progress over the next several quarters.
Margin Expansion And Cost SavingsHigher gross and adjusted EBITDA margins, supported by identified cost savings, improve the earnings conversion of future revenue. The additional annualized savings planned for 2027 could provide a durable offset to cost pressure and strengthen operating leverage.
Product Relaunch And Supply RecoveryRestored manufacturing and progress in product relaunches can rebuild availability, customer confidence, and revenue in important regenerative technology categories. Continued PriMatrix recovery and the planned SurgiMend relaunch create identifiable avenues for portfolio improvement.
Bears Say
Elevated LeverageLeverage remains high relative to the company’s current earnings base, limiting financial flexibility while Integra funds operations and portfolio recovery. Refinancing may also increase interest expense, leaving less cash available for investment, debt reduction, or resilience against setbacks.
Loss-making And Volatile ProfitabilityA return to losses shows that revenue growth has not yet translated into dependable bottom-line earnings. Volatile operating profitability makes cash planning and capital allocation more difficult, while sustained margin pressure could weaken the company’s ability to reduce leverage.
Portfolio Competition And Segment WeaknessWeakness across tissue reconstruction and ENT indicates that portfolio growth is uneven rather than broad-based. New competitors in MicroMatrix may pressure pricing, adoption, and share, making it harder for Integra to convert relaunch efforts and surgical demand into durable growth.
Integra Lifesciences News
IL3 FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was €7.60 and its highest was €17.30 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is €1.10B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Nov 04, 2026 which is in 37 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Jul 29, 2026. The company reported €0.48 earnings per share for the quarter, beating the consensus estimate of €0.412 by €0.068.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. does not currently pay dividends.
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.48.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,772,510 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of €0.48 in its last earnings report, beating expectations of €0.412. Following the earnings report the stock price went up 1.183%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in DE:IL3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integra Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€15.96 (10.84% Upside)
€15.96 (10.84% Upside)
Blogger Sentiment
Bullish
DE:IL3 Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
IL3 Company Deck
IL3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized steady, constructive progress: revenue and EPS tracked to guidance with meaningful margin expansion, improved operating cash flow, successful product relaunch momentum (PriMatrix) and a key operational milestone with Braintree restarting to enable the SurgiMend relaunch. Management reaffirmed full-year organic growth and adjusted EPS guidance while outlining cost savings and deleveraging priorities. Offsetting positives are softness in tissue reconstruction and ENT, competitive pressure on MicroMatrix, continued high net debt and the timing risk tied to FDA inspections and refinancing-related interest expense. Overall the positives (execution, margin/cash improvement, product relaunches and supply recovery) substantially outweigh the headwinds, though timing and leverage risks remain.)View all DE:IL3 earnings summariesIL3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€15.96
▲(10.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











